Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shepherd, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


The role of the exogenous pathway in hypercholesterolaemia

J. Shepherd*

Royal Infirmary, Glasgow, Scotland, U.K.

* Correspondence: Professor James Shepherd, MB, ChB, PhD, Department of Pathological Biochemistry, University of Glasgow, and Royal Infirmary, 84 Castle Street, Glasgow, Scotland G4 0SF, U.K.

Abstract

The concentration of plasma cholesterol is regulated by endogenous and exogenous pathways of cholesterol metabolism. In the endogenous pathway, cholesterol is synthesized by the liver and extrahepatic tissues, and enters the circulation as a component of lipoproteins, or is secreted into bile. In the exogenous pathway, cholesterol from dietary and biliary sources is absorbed in the intestine and ultimately enters the circulation as a component of chylomicrons. A new class of drugs, the selective cholesterol absorption inhibitors, offers a different approach to current strategies available for the management of hypercholesterolaemia. Ezetimibe, the first of these new compounds, inhibits intestinal absorption of dietary and biliary cholesterol, and lowers total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels in humans. By inhibiting cholesterol absorption, and thereby possibly reducing the cholesterol content of chylomicrons, ezetimibe may also decrease the potential atherogenicity of chylomicrons and their remnants. Combination therapy with ezetimibe and statins, which inhibit cholesterol synthesis, provides broader control of lipid levels by impacting both the exogenous and endogenous pathways of cholesterol metabolism. Such combination therapy may be a convenient and more practical option for LDL-C reduction.

Key Words: Exogenous cholesterol pathway • hypercholesterolaemia • cholesterol metabolism • cholesterol absorption inhibition • ezetimibe • statins

References

  1. Witztum JL. Drugs used in the treatment of hyperdyslipidemias. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th edn. New York: McGraw-Hill International Book Co; 1996. p. 875–897 chap 36
  2. Beisiegel U. Lipoprotein metabolism. Eur Heart J. 1998;19(Suppl A):A20–A23
  3. Russell DW. Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther. 1992;6:103–110[CrossRef][Web of Science][Medline]
  4. Faggiotto A, Paoletti R. Statins and blockers of the renin-angiotensin system. Vascular protection beyond their primary mode of action. Hypertension. 1999;34:987–996 (pt 2)[Abstract/Free Full Text]
  5. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci. 1999;65:1329–1337[CrossRef][Medline]
  6. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998;82:3J–10J[CrossRef][Web of Science][Medline]
  7. Blum CB. Comparison of the properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 1994;73:3D–11D (Suppl)[CrossRef][Medline]
  8. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678–682[Abstract/Free Full Text]
  9. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am. 2000;84:23–42[CrossRef][Web of Science][Medline]
  10. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511[Free Full Text]
  11. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet. 1997;32:403–425[Web of Science][Medline]
  12. Dujovne CA, Chremos AN, Pool JL, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 1991;91(Suppl 1B):25S–30S[CrossRef][Medline]
  13. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235 and its glucuronide, SCH60663 Br J Pharmacol. 2000;129:1748–1754[CrossRef][Web of Science][Medline]
  14. van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235 in the rat and rhesus monkey through the identification of the active metabolites of SCH48461 J Pharmacol Exp Ther. 1997;283:157–163[Abstract/Free Full Text]
  15. Dawson PA, Rudel LL. Intestinal cholesterol absorption. Curr Opin Lipidol. 1999;10:315–320[CrossRef][Web of Science][Medline]
  16. Patsch J. Influence of lipolysis on chylomicron clearance and HDL cholesterol levels. Eur Heart J. 1998;19(Suppl H):H2–H6
  17. Mamo JCL. Atherosclerosis as a post-prandial disease. Endocrinol Metab. 1995;2:229–244
  18. Proctor SD, Pabla CK, Mamo JCL. Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis. 2000;149:315–322[CrossRef][Medline]
  19. Mamo JCL, Smith D, Yu KCW, et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemia. Eur J Clin Invest. 1998;28:379–384[CrossRef][Web of Science][Medline]
  20. Cohn JS. Postprandial lipemia: emerging evidence for atherogenicity of remnant lipoproteins. Can J Cardiol. 1998;14(Suppl B):18B–27B
  21. Phillips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis. 2000;148:283–291[CrossRef][Web of Science][Medline]
  22. Mamo JC, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis. 1998;141(Suppl 1):S63–S69
  23. Davis HR, Compton DS, Hoos L, Tetzloff G, Caplen MA, Burnett DA. Ezetimibe (SCH58235 localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption (Abstr). Eur Heart J. 2000;21:636 (Suppl)
  24. van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol. 2001;415:79–84[CrossRef][Web of Science][Medline]
  25. Dietschy JM. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr. 1997;65:1581S–1589S (Suppl)[Abstract/Free Full Text]
  26. Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin (Abstr). Atherosclerosis. 2000;151:135

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
V. F Mauro and C. E Tuckerman
Ezetimibe for Management of Hypercholesterolemia
Ann. Pharmacother., June 1, 2003; 37(6): 839 - 848.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shepherd, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?